Cytarabine dose in the consolidation treatment of AML: a systematic review and meta-analysis

Blood. 2017 Aug 17;130(7):946-948. doi: 10.1182/blood-2017-04-777722. Epub 2017 Jul 5.

Authors

Kinkini N Magina¹, Gudrun Pregartner², Armin Zebisch¹, Albert Wölfler¹, Peter Neumeister¹, Hildegard T Greinix¹, Andrea Berghold², Heinz Sill¹

Affiliations

¹ Division of Hematology, Department of Internal Medicine, and.
² Institute of Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.

PMID: 28679736
DOI: 10.1182/blood-2017-04-777722

No abstract available

Publication types

Letter
Meta-Analysis
Review
Systematic Review

MeSH terms

Adolescent
Adult
Aged
Antimetabolites, Antineoplastic / administration & dosage
Antimetabolites, Antineoplastic / adverse effects
Antimetabolites, Antineoplastic / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Child
Child, Preschool
Consolidation Chemotherapy*
Cytarabine / administration & dosage
Cytarabine / adverse effects
Cytarabine / therapeutic use*
Dose-Response Relationship, Drug
Female
Humans
Infant
Leukemia, Myeloid, Acute / drug therapy*
Male
Middle Aged
Remission Induction
Survival Analysis
Young Adult

Substances

Antimetabolites, Antineoplastic
Cytarabine